TSHA FY 2023 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+517.5% YoY

Gross Profit

$15M100.0% margin

Operating Income

-$72M-468.8% margin

Net Income

-$112M-722.1% margin

EPS (Diluted)

$-0.96

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$80M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$173M

Total Liabilities

$98M

Stockholders' Equity

$75M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$3M	+517.5%
Gross Profit	$15M	$14,999	+102913.5%
Operating Income	-$72M	-$126M	+42.5%
Net Income	-$112M	-$166M	+32.8%